The cash cow of medicines in Belgium: reform or preserve?
Pieter Van Herck, Lieven Annemans, Ivan Van de Cloot
Government policy targets the price and volume of medicine use to cut healthcare spending. In
this analysis, Itinera examines the need and potential for such reforms, what are the advantages
and disadvantages, and how to proceed further. The need for reform is substantial in short
term, with a potential of 444 million euro in yearly savings because of price competition after patent
expiry. In the long run, a refocusing towards evidence based medicine use is needed to partially
address the issue of rising care expenditure.
Download our analysis FR NL
The future of Health Care: diagnosis & treatments
The Belgian Healthcare system possesses numerous assets, but is also seriously threatened by the new challenges of the 21st century. Even if these challenges are numerous,it is not too late to act.
But if we do not react on time, we won’t be able to continue to assure the access to care, its quality, while mastering its costs.
To guarantee the future of our healthcare system, we suggest a set of concrete and innovative actions for a sustainable system.
Related events & forum
What others think about this